Treatment of Laryngopharyngeal Reflux Disease: A Systematic Review Publisher



Lechien JR^{1, 2} ; Mouawad F^{2, 3} ; Barillari MR^{2, 4} ; Nacci A^{2, 5} ; Khoddami SM^{2, 6} ; Enver N^{2, 7} ; Raghunandhan SK^{2, 8} ; Calvohenriquez C^{2, 9} ; Eun YG^{2, 10} ; Saussez S^{1, 2} Show Affiliations
Source: World Journal of Clinical Cases Published:2019

Abstract

BACKGROUNG For a long time, laryngopharyngeal reflux disease (LPRD) has been treated by proton pump inhibitors (PPIs) with an uncertain success rate. AIM To shed light the current therapeutic strategies used for LPRD in order to analysis the rationale in the LPRD treatment. METHODS Three authors conducted a PubMed search to identify papers published between January 1990 and February 2019 about the treatment of LPRD. Clinical prospective or retrospective studies had to explore the impact of medical treatment(s) on the clinical presentation of suspected or confirmed LPRD. The criteria for considering studies for the review were based on the population, intervention, comparison, and outcome framework. RESULTS The search identified 1355 relevant papers, of which 76 studies met the inclusion criteria, accounting for 6457 patients. A total of 64 studies consisted of empirical therapeutic trials and 12 were studies where authors formally identified LPRD with pH-monitoring or multichannel intraluminal impedance-pH monitoring (MII-pH). The main therapeutic scheme consisted of once or twice daily PPIs for a duration ranged from 4 to 24 wk. The most used PPIs were omeprazole, esomeprazole, rabeprazole, lansoprazole and pantoprazole with a success rate ranging from 18% to 87%. Other composite treatments have been prescribed including PPIs, alginate, prokinetics, and H2 Receptor antagonists. CONCLUSION Regarding the development of MII-pH and the identification of LPRD subtypes (acid, nonacid, mixed), future studies are needed to improve the LPRD treatment considering all subtypes of reflux. © The Author(s) 2019.